Cargando…
Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates, statins or both?
Although less clinical intervention studies have been performed with fibrates than with statins, there are evidences indicating that fibrates may reduce risk of cardiovascular events. The potential clinical benefit of the fenofibrate will be specified by the ongoing Fenofibrate Intervention and Even...
| Autores principales: | , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2004
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC538252/ https://www.ncbi.nlm.nih.gov/pubmed/15574199 http://dx.doi.org/10.1186/1475-2840-3-10 |